Arrowhead Pharmaceuticals (ARWR) 10-Q2011 Q1 Quarterly report

Filed: 10 Feb 11, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. freshman Avg

New words: Anderson, Article, ascertain, ascribed, assay, attorney, audit, audited, biology, cartilage, cell, Center, cooperation, culture, cure, default, essentially, foreseen, headcount, interface, maximum, mid, molecular, multistage, nanoengineering, nanomedicine, obesity, partially, patient, pioneering, read, recession, recruitment, redevelopment, renegotiated, Republic, Similarly, site, spending, stable, stem, temporarily, tied, tissue, unacceptable, unchanged, unmet, Wisepower, withholding, write

Removed: Academy, accelerated, added, adding, addressing, adequate, Advancing, aging, alternative, Alternatively, amortizable, amyotrophic, analyzing, anniversary, applied, approval, arsenide, Asia, assessment, assure, attendant, automatically, bear, bearing, begun, Benet, biotechnology, borne, brain, building, bulk, cadmium, calculate, calculated, callable, cancel, cancelled, candidate, capture, carbide, carboxylated, carried, checking, climate, closely, closure, CNI, CNT, collateral, commitment, committed, community, compare, comparison, composed, composition, computed, concentrate, Concentration, conductive, constituent, continuation, contracted, contractual, convert, coordinated, Council, covering, culminating, Cyclosert, data, decided, declined, delayed, deliver, demonstrated, deposit, depreciable, designed, device, dilutive, direct, discretion, disposal, disposition, dose, doubtful, dramatic, dramatically, durability, duration, efficacy, efficiency, effort, electric, electronic, employ, enable, enacted, Ensysce, environment, environmental, escalation, established, ethical, evidenced, evolve, exceeded, exclusively, explore, extremely, failed, FDA, FDIC, Ferrari, film, final, Florida, foreseeable, forfeiture, format, forward, gallium, Gehrig, germanium, halt, high, highest, holding, Ia, Ib, ii, impede, incomplete, incorporating, incumbent, IND, indium, infrastructure, initially, insured, integrated, intensive, interrupted, inventory, investigational, lead, leading, lease, leasehold, lesser, limitation, liquid, liquidation, lost, Lou, mature, maturity, Mauro, Menlo, metal, modified, monetize, monthly, move, nanoparticle, nanosilver, nanotube, National, network, nitride, nominal, obligation, obstacle, oncology, pace, panel, paper, Park, Parkinson, partnering, performed, periodically, phosphide, pipeline, plant, point, positioned, preference, preliminary, preparatory, preparing, present, preserve, privately, processing, produce, producing, profile, prohibit, proportionate, prospectively, protocol, pursuing, ranging, receipt, redeemed, referred, regulate, repeated, requiring, resource, resulted, retrospectively, reviewing, Rice, RNA, RNAi, robust, RONDEL, round, running, safety, schizophrenia, secondarily, secured, selenide, shape, simple, smaller, social, solar, solve, solvency, statutory, storage, streamline, study, subordinated, supplier, supported, suspension, targeted, targeting, taxable, TCF, tested, testing, thereon, thin, touch, transparent, trauma, uncertainty, uncollectible, undergoing, understood, undiscounted, unforeseen, uninsured, unsafe, utilizing, vertically, vested, viewed, voluntary, wealth, workforce, York

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

ARWR similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO RULE 13a-14(b) OR RULE 15d-14(b)

OF THE SECURITIES EXCHANGE ACT OF 1934

AND 18 U.S.C. SECTION 1350

I, Christopher Anzalone, Chief Executive Officer of Arrowhead Research Corporation (the “Company”), certify, pursuant to Rule 13(a)-14(b) or Rule 15(d)-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350, that (i) the Quarterly Report on Form 10-Q of the Company for the quarterly period ended June 30, 2010, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and (ii) the information contained in such Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of the Company.

Date: February 10, 2010

/S/ CHRISTOPHER ANZALONE

Christopher Anzalone

Chief Executive Officer

A signed original of these written statements required by 18 U.S.C. Section 1350 has been provided to Arrowhead Research Corporation and will be retained by Arrowhead Research Corporation and furnished to the Securities and Exchange Commission or its staff upon request.